Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
Desmopressin (DDAVP)9 residuesCYFQNCPRGEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: DDAVP, dDAVP, desmopressin acetate
FDA-approved since 1978 with over 6,688 PubMed papers behind it, desmopressin is one of the longest-running peptide therapies in medicine. This synthetic vasopressin analog (DDAVP, 1-desamino-8-D-arginine vasopressin) selectively targets V2 receptors in the kidney, replacing missing antidiuretic hormone in patients with central diabetes insipidus. It also doubles as a hemostatic agent, boosting factor VIII and von Willebrand factor 3 to 5 fold within 30 to 60 minutes. The catch: it holds onto water. Drinking beyond thirst while on desmopressin can drop sodium to dangerous levels, and that risk never goes away. Patients with central DI, nocturnal enuresis, and mild hemophilia A rely on it daily.
Over 6,688 published studies and 45 years of continuous clinical use put desmopressin among the most thoroughly documented peptide therapies available. Known as DDAVP (1-desamino-8-D-arginine vasopressin, CAS 16679-58-6), this nine amino acid synthetic analog of vasopressin earned its first FDA approval in 1978. Three labeled indications remain active today: central diabetes insipidus, primary nocturnal enuresis in patients six and older, and hemostatic management of mild hemophilia A and type 1 von Willebrand disease. Two structural changes separate desmopressin from native vasopressin. Deamination at position 1 and D-arginine substitution at position 8 deliver roughly 10 fold greater antidiuretic potency, a longer half-life (mean 3.1 hours subcutaneous per)[1], and almost zero vasopressor activity. That selectivity for the V2 receptor is the entire point; you get water retention without blood pressure effects. In real-world use, central DI patients describe desmopressin as life-changing. Drugs.com reviews average 9.1 out of 10 across 44 ratings. Nocturnal enuresis trials show roughly 70% response rates with oral dosing. For hemostasis, a single 0.3 mcg/kg IV dose raises factor VIII 3 to 5 fold within 30 to 90 minutes, covering minor surgical and dental procedures without blood products (Mannucci PM, Blood 1997;)[2]. Four formulations exist: injectable (4 mcg/mL for IV or subcutaneous use), intranasal spray, oral tablets (0.1 and 0.2 mg), and the newest option, Desmoda oral solution (0.05 mg/mL, FDA-approved February 2026). Hyponatremia remains the primary safety concern across all routes and all indications. Fluid restriction is not optional.
Desmopressin binds selectively to vasopressin V2 receptors, a Gs-protein coupled receptor sitting on the basolateral membrane of principal cells in the renal collecting duct. Activation triggers adenylate cyclase, raising intracellular cyclic AMP and switching on protein kinase A. PKA then phosphorylates aquaporin-2 water channel proteins stored inside vesicles, pushing them to the apical membrane. The result is a water-permeable pathway that pulls water from the tubular lumen back into the medullary interstitium. Urine output drops; urine concentration rises. That same V2 receptor appears on vascular endothelial cells. When desmopressin activates it there, the cAMP/PKA cascade triggers exocytosis of Weibel-Palade bodies. These specialized storage organelles release large von Willebrand factor multimers and factor VIII into the bloodstream. Circulating VWF and factor VIII levels jump 3 to 5 fold within 30 to 90 minutes. Platelet adhesion improves. The intrinsic coagulation cascade accelerates. Two engineering changes make all of this possible without the vasopressor effects of native vasopressin. Deamination at cysteine position 1 blocks V1a receptor binding (the receptor responsible for vasoconstriction). D-arginine at position 8 resists enzymatic degradation, extending the half-life from roughly 10 minutes for vasopressin to about 3.1 hours for desmopressin [1]. Selectivity and durability in nine amino acids.
FDA-approved since 1978; first-line for central diabetes insipidus (AVP-D), primary nocturnal enuresis (≥6 yr), and hemostatic management of mild hemophilia A / type 1 VWD. ~6,688 PubMed papers. Strong evidence for all three labeled indications. 2024 meta-analysis found worse neurological outcomes with DDAVP in antiplatelet-associated ICH: routine use in that setting not supported.
Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood. 1997;90(7):2515-2521. PMID 10982270
Hemostatic tachyphylaxis limits use to 2–3 consecutive doses (≥48h apart; Weibel-Palade body depletion). Hyponatremia risk requires strict fluid management. Contraindicated in CrCl <50 mL/min. ~10–15% of hemostatic patients are non-responders. 2024 ICH meta-analysis (PMID 38778788) shows poor neurological outcomes: avoid off-label use in antiplatelet-associated intracranial hemorrhage.
Considered life-changing by central DI patients. Highly effective for nocturnal enuresis in children. Well-tolerated long-term with proper monitoring. Primary community concerns: cost without insurance, 2025 nasal spray shortage (resolved Dec 2025), and maintaining fluid discipline to prevent hyponatremia.
Community use mirrors clinical evidence exactly: desmopressin is used exclusively for its FDA-approved indications. No off-label performance or wellness use. Patient concerns (cost, fluid management, tachyphylaxis, supply disruptions) align with clinically documented limitations.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 2mcg | Daily |
| Moderate | 2mcg | 1-2x Daily |
| Aggressive | 4mcg | 1-2x Daily |
Desmopressin injectable comes ready to use at 4 mcg/mL. No reconstitution needed. Draw directly from the vial with an insulin syringe. For the standard DI dose of 2 mcg: that is 0.5 mL from the 4 mcg/mL vial, which reads as 50 units on a U-100 insulin syringe. A 4 mcg dose is 1.0 mL, or 100 units on the same syringe. Store vials refrigerated at 2 to 8 degrees Celsius. Room temperature (20 to 25 degrees) is fine for up to 3 weeks if needed, but don't freeze it. The biggest mistake new DI patients make is drinking out of habit. You've spent months or years guzzling water to keep up with polyuria. Once desmopressin kicks in, that habit becomes dangerous. Drink only when genuinely thirsty, nothing more. If you're switching from injectable to oral tablets, multiply your dose significantly. Oral bioavailability is 0.08 to 0.16 percent versus nearly 100 percent subcutaneous. Your doctor will recalculate, and sodium needs rechecking within a week.
Desmopressin is used continuously for diabetes insipidus (no cycling needed) or on an as-needed basis for hemostatic indications. For hemophilia A/VWD, doses should be spaced at least 48 hours apart to avoid tachyphylaxis. Serum sodium should be monitored regularly, especially when initiating therapy or adjusting dose. Fluid intake must be restricted to minimize hyponatremia risk.
Desmopressin does not follow conventional peptide cycling. Central DI requires continuous daily dosing as permanent hormone replacement: no off periods appropriate or safe. For hemostatic use (hemophilia A/VWD), doses must be spaced ≥48 hours apart to allow Weibel-Palade body replenishment after depletion: this is indication-specific timing, not cycling. No receptor tolerance develops with continuous DI use. The cyclingProtocol.onWeeks/offWeeks: 0 in peptides.ts correctly reflects the absence of cycling.
Or use the universal Peptide Calculator for any peptide.
Expected: Urine output normalized (<2.5 L/day); urine osmolality >300 mOsm/kg; serum sodium maintained at 136–145 mEq/L; resolution of polydipsia, nocturia, and sleep disruption
Monitor: Serum sodium: baseline, 1 week after initiation, after any dose change, then every 3–6 months. Monitor fluid intake: drink only to satisfy thirst, never prophylactically.
Gather the desmopressin vial (4 mcg/mL), a U-100 insulin syringe (29 or 30 gauge), and an alcohol swab.
Inspect the solution for clarity. It should be colorless and particle-free.
Wipe the vial stopper with the alcohol swab.
For a 2 mcg dose, draw to the 50-unit mark on the U-100 insulin syringe (0.5 mL). For a 4 mcg dose, draw to the 100-unit mark (1.0 mL).
Choose an injection site: abdomen (two inches from the navel) or outer thigh. Rotate sites between doses.
Let it dry.
Pinch the skin, insert the needle at a 45 to 90 degree angle, and inject slowly. Release the pinch and withdraw.
Do not rub the injection site afterward.
For DI dosing, administer morning and/or evening based on when symptoms are worst. Most patients need twice-daily injections initially.
For hemostatic use (0.3 mcg/kg IV), this is typically administered in a clinical setting by a healthcare provider. Dilute in 50 mL normal saline, infuse over 15 to 30 minutes.
Restrict fluid intake to what thirst requires, starting immediately after your dose. This is not optional.
Record the dose and time for your next sodium check.
Same weight-based dose as SC (0.3 mcg/kg); must be diluted in 50 mL 0.9% NaCl and infused over 15–30 min
More reliable factor VIII/VWF response than SC for hemostasis. Higher rate of flushing vs SC. Not typically available for outpatient self-administration.
~3–5% bioavailability vs ~100% SC; DI dose 10–40 mcg intranasal (vs 2–4 mcg SC). Stimate 1.5 mg/mL spray used for hemostatic indication (higher concentration than standard DDAVP nasal spray).
2025 nasal spray shortage (resolved Dec 2025) disrupted many DI patients. Recommend having backup oral or injectable prescription to avoid supply-related lapses.
0.08–0.16% oral bioavailability. Oral doses 0.1–0.4 mg equivalent to ~1–4 mcg SC. Cannot be split accurately for pediatric titration.
Cheapest long-term option (~$35.62 GoodRx per 60 tablets). Slower onset than SC/IV. Dose recalculation required when switching from injectable.
Same oral bioavailability as tablets; enables precise dose titration without tablet splitting. Available via specialty pharmacy Anovo with Eton Cares patient assistance program.
Particularly valuable for pediatric patients and adults requiring sub-0.1 mg doses. Ready-to-use liquid; no refrigeration required. Pricing not yet established at time of data collection.
Potentiate antidiuretic effect via SIADH-like mechanism, significantly increasing hyponatremia risk; FDA label warning
Do not combinePotentiates antidiuretic effect markedly; listed explicitly in FDA label as hyponatremia risk
Do not combineCombined with desmopressin increases water retention and hyponatremia risk; FDA label lists as increased risk
Do not combineIncrease risk of water retention and hyponatremia when combined with desmopressin
Pricing updated 2026-04-09
Hyponatremia is the safety issue that defines desmopressin therapy. Because the drug tells kidneys to hold onto water, drinking beyond thirst dilutes blood sodium. Mild cases cause headache, nausea, and fatigue. Severe drops below 125 mEq/L bring confusion, seizures, coma, and in rare cases death. This is not a theoretical concern; the FDA label carries the warning prominently, and sodium monitoring is mandatory before starting therapy and after every dose change. Risk groups deserve particular attention. Young children lack the body awareness to limit fluid intake on their own. Elderly patients have reduced renal concentrating ability that masks early warning signs. Anyone taking SSRIs, carbamazepine, tricyclic antidepressants, or NSAIDs faces compounded risk, because these medications independently promote water retention through SIADH-like mechanisms. The FDA label lists each of these drug classes explicitly. Loperamide raises a less obvious flag. It increases desmopressin plasma concentrations up to 3 fold through intestinal absorption effects. Taking both together amplifies every desmopressin effect and side effect simultaneously. Facial flushing is common with intravenous administration and typically resolves within minutes. Headache, dizziness, nausea, and abdominal cramps appear across all routes at moderate frequency. Intranasal use adds nasal congestion to the list. Subcutaneous injection can produce mild site reactions. Rare but documented events include anaphylaxis, transient blood pressure changes, and thrombotic events in patients with pre-existing risk factors. For hemostatic use specifically, tachyphylaxis is a real limitation. Doses given less than 48 hours apart deplete endothelial Weibel-Palade body stores faster than the body can replenish them. Factor VIII and VWF response diminishes with each dose. This is why the FDA label restricts hemostatic dosing to every 48 hours minimum, and why desmopressin cannot cover multi-day major surgeries. Roughly 10 to 15 percent of hemostatic patients never respond adequately; a test dose before surgical reliance is standard practice. Contraindications are firm. Patients with existing hyponatremia or a history of it should not receive desmopressin. Renal impairment (creatinine clearance below 50 mL/min) is an absolute contraindication per FDA labeling, because reduced clearance causes drug accumulation and amplifies hyponatremia risk. Primary polydipsia (habitual overdrinking) makes safe desmopressin use nearly impossible. Pregnancy falls under FDA Category B. Use only when clearly needed. Desmopressin appears in breast milk in negligible amounts, but infants should still be monitored for hyponatremia signs. When to seek immediate medical attention: persistent headache with nausea and confusion after taking desmopressin, or any seizure activity. Stop the drug, restrict fluids, and get serum sodium measured. If sodium reads below 125 mEq/L or neurological symptoms are present, emergency treatment with hypertonic saline may be required.
Verify Desmopressin (DDAVP) dosing and safety with a second opinion
FDA-regulated pharmaceutical requiring a valid prescription. Produced under GMP conditions by licensed manufacturers. Not a gray-market research chemical. Standard of care for three established indications.
| Test | When | Target |
|---|---|---|
| Serum sodium | Before initiation; 1 week after starting or any dose change; every 3–6 months during stable therapy | 136–145 mEq/L |
| Urine osmolality | During DI dose titration; periodically at follow-up visits | >300 mOsm/kg (concentrated urine confirms V2 receptor activation) |
| 24-hour urine volume | During DI initiation and titration phase; periodically during maintenance | <2.5 L/day |
| Factor VIII activity and VWF:RCo | 30 and 60 min after test dose (hemostatic indication); optional after subsequent treatment doses | Factor VIII ≥50 IU/dL post-dose for surgical hemostasis coverage |
| Renal function (serum creatinine / CrCl) | Before initiation | CrCl ≥50 mL/min required to initiate |
Detect hyponatremia: primary serious adverse effect; mandatory per FDA label. Risk highest within first 2 weeks of therapy.
Confirms adequate antidiuretic response and guides dose adjustment
Primary clinical endpoint for DI control; quantifies antidiuretic response
Confirms adequate hemostatic response before surgical reliance; identifies non-responders (~10–15% of patients)
CrCl <50 mL/min is an FDA label contraindication: drug accumulates and dramatically increases hyponatremia risk
Onset of antidiuretic effect following SC/IV administration; initial reduction in urine output begins
Peak plasma levels achieved; factor VIII and VWF levels peak at 3- to 5-fold above baseline for hemostatic use
Maximum urine concentration achieved; antidiuretic effect fully established
Duration of antidiuretic effect; urine output returns toward baseline as drug is cleared
Stable dose titration for diabetes insipidus achieved; consistent control of urine volume and serum sodium
15 to 30 minutes after a subcutaneous or IV dose: V2 receptor activation kicks off the cAMP/PKA cascade and pushes aquaporin-2 channels into position. Urine output starts dropping. DI patients notice the reduced urge to urinate within this window. Hemostasis patients may see early bleeding slowdown. Facial flushing is common with IV administration; mild headache and transient nausea can appear. 30 to 90 minutes: peak antidiuretic and hemostatic effect. Urine osmolality hits maximum. Factor VIII and VWF levels peak at 3 to 5 fold above baseline for hemostatic use (plasma Tmax roughly 60 minutes subcutaneous). DI patients enter a dry period with reduced thirst. Hemostatic patients report bleeding control adequate for dental or minor surgical procedures. 6 to 12 hours post-dose: the drug clears (half-life about 3.1 hours subcutaneous) and the antidiuretic window closes. Urine output drifts back toward baseline. Most DI patients need twice-daily dosing to stay covered. Once nightly works for enuresis. A return of mild thirst signals the next dose window. 1 to 2 weeks: stable dose titration for DI. Most patients land at 2 to 4 mcg per day subcutaneous. Consistent control of urine volume and serum sodium should be established by now. Patients describe feeling normal again: sleeping through the night, no constant thirst, dramatically better quality of life. Hyponatremia risk peaks in this titration window if fluid intake is not restricted. Long-term (months to years): effective maintenance with no tolerance development for DI use. The hemostatic tachyphylaxis concern does not apply to continuous antidiuretic dosing. Dose adjustments may be needed if pituitary function changes post-surgery or post-trauma. Community concerns center on insurance coverage, cost ($134 to $800 per vial depending on brand vs. generic), and supply reliability after the 2025 nasal spray shortage (resolved December 2025).
V2 receptor activation → cAMP/PKA cascade → AQP2 channel translocation to apical membrane; first measurable reduction in urine output
DI patients notice reduced urge to urinate within 15–30 min after injection; hemostasis patients experience bleeding slowdown
Maximum urine osmolality; factor VIII and VWF:RCo peak at 3–5× baseline for hemostatic use; plasma Tmax ~60 min SC
DI patients enter dry period with reduced thirst. Hemostatic patients report bleeding cessation adequate for dental or minor surgical procedures.
Effect declines as drug is cleared (t½ ~3.1h SC); urine output returns toward baseline by 6–12h
Most DI patients need twice-daily dosing; once nightly sufficient for enuresis. Return of mild thirst signals next dose time.
Dose titrated to optimal level based on 24h urine volume, urine osmolality, and serum sodium; most patients stabilize at 2–4 mcg/day SC
Patients describe feeling "normal": sleeping through the night, no constant thirst, dramatically improved quality of life
Effective long-term control with no tolerance development (unlike hemostatic tachyphylaxis). Dose may need adjustment if underlying pituitary function changes post-surgery or trauma.
Life-changing for DI patients long-term. Ongoing concerns: insurance coverage, cost ($134–$800/vial), and supply reliability highlighted by 2025 nasal spray shortage.
Source: Mean t½ 3.1 hours (range 2.7-4.6 h) in healthy subjects after subcutaneous injection (Eur J Clin Pharmacol 1988; PMID 3141199)
Loading the interactive decay curve.
Desmopressin (DDAVP) holds full FDA approval for three indications: central diabetes insipidus, primary nocturnal enuresis (patients six years and older), and hemostatic management of mild hemophilia A and type 1 von Willebrand disease. First approved in 1978, it has maintained continuous FDA approval for over 45 years. This is a prescription medication. All formulations (injectable, intranasal spray, oral tablets, and Desmoda oral solution approved February 2026) require a valid prescription from a licensed healthcare provider. Generic versions are available from multiple FDA-regulated manufacturers. Desmopressin is not a controlled substance. It is not on the WADA prohibited list, though athletes using it for medical reasons should check current anti-doping regulations with their sport's governing body. The content on this page is for informational and educational purposes only. It does not constitute medical advice. Consult a qualified healthcare provider before starting or changing any medication. Desmopressin requires regular sodium monitoring and physician oversight for safe long-term use.
Peptide Schedule Research TeamReviewed Apr 20269 Citations
